Hepatitis B in the Human Immunodeficiency Virus-Infected Patient: Epidemiology, Natural History, and Treatment

Chloe L. Thio

doi:10.1055/s-2003-39951

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2003; 23(2): 125-136
DOI: 10.1055/s-2003-39951

Hepatitis B in the Human Immunodeficiency Virus-Infected Patient: Epidemiology, Natural History, and Treatment

Chloe L. Thio

Assistant Professor of Medicine, Johns Hopkins University, Baltimore, Maryland

Abstract

ABSTRACT

Coinfection with hepatitis B virus (HBV) is common in the human immunodeficiency virus-1 (HIV)-infected patient because of shared modes of transmission. HBV does not appear to alter HIV disease progression; however, HBV infection is more frequent and more severe in the HIV-infected population, emphasizing the importance of preventing HBV infection. The goal of anti-HBV therapy is prevention of cirrhosis because therapy does not eradicate the hepatic reservoirs (cccDNA). The approved therapies-interferon-alfa, lamivudine, and adefovir-each have a niche in the treatment of chronic hepatitis B in the HIV-infected population, but none has been well-studied in this setting. As new drugs currently in clinical trials become available, therapy for chronic hepatitis B will enter the promising era of combination therapy.

KEYWORDS

HIV - hepatitis B - interferon-alfa - lamivudine - adefovir

Full Text

References

REFERENCES

1 Mahoney F J. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev . 1999; 12 351-366
2 Homann C, Krogsgaard K, Pedersen C, Andersson P, Nielsen J O. High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection. J Acquir Immune Defic Syndr . 1991; 4 416-420
3 Rustgi V K, Hoofnagle J H, Gerin J L. et al . Hepatitis B virus infection in the acquired immunodeficiency syndrome. Ann Intern Med . 1984; 101 795-797
4 Centers for Disease Control and Prevention. 1999 USPHS/ IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. USPHS/IDSA Prevention of Opportunistic Infections Working Group. US Public Health Services/Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rept . 1999; 48 1-82
5 MacKellar D A, Valleroy L A, Secura G M. et al . Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health . 2001; 91 965-971
6 Kao J H. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol . 2002; 17 643-650
7 Kao J H, Chen P J, Lai M Y, Chen D S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology . 2000; 118 554-559
8 Hollinger F B. Hepatitis B virus. In: Knipe DM, Howley PM, et al, eds. Virology, 4th ed Philadelphia: Lippincott Williams and Wilkins 2001: 2971-3036
9 Sakai T, Shiraki K, Inoue H. et al . HBV subtype as a marker of the clinical course of chronic HBV infection in Japanese patients. J Med Virol . 2002; 68 175-181
10 Coleman P J, McQuillan G M, Moyer L A, Lambert S B, Margolis H S. Incidence of hepatitis B virus infection in the United States, 1976-1994; estimates from the National Health and Nutrition Examination Surveys. J Infect Dis . 1998; 178 954-959
11 McQuillan G M, Coleman P J, Kruszon-Moran D. et al . Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health . 1999; 89 14-18
12 Kingsley L A, Rinaldo Jr R C, Lyter D W. et al . Sexual transmission efficiency of hepatitis B virus and human immunodeficiency virus among homosexual men. JAMA . 1990; 264 230-234
13 Levine O S, Vlahov D, Koehler J. et al . Seroepidemiology of hepatitis B virus in a population of injecting drug users- association with drug injection patterns. Am J Epidemiol . 1995; 142 331-341
14 Centers for Disease Control and Prevention. Recommendations for protection against viral hepatitis. MMWR Morb Mortal Wkly Rept . 1985; 34 313-335
15 Rehermann B, Ferrari C, Pasquinelli C, Chisari F V. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med . 1996; 2 1104-1108
16 McMahon B J, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med . 2001; 135 759-768
17 Liaw Y F, Tai D I, Chu C M, Chen T J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology . 1988; 8 493-496
18 Fattovich G, Brollo L, Giustina G. et al . Natural history and prognostic factors for chronic hepatitis type B. Gut . 1991; 32 294-298
19 Yang H I, Lu S N, Liaw Y F. et al . Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med . 2002; 347 168-174
20 Beasley R P, Hwang L Y, Lin C C, Chien C S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22707 men in Taiwan. Lancet . 1981; 2 1129-1133
21 Fattovich G, Rugge M, Brollo L. et al . Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology . 1986; 6 167-172
22 de Jongh E F, Janssen H L, De Man A R. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology . 1992; 103 1630-1635
23 Davis G L, Hoofnagle J H, Waggoner J G. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology . 1984; 86 230-235
24 Torbenson M, Thomas D L. Occult hepatitis B. Lancet Infect Dis . 2002; 2 479-486
25 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. HIV Clin Trials . 2001; 2 493-554
26 Hofer M, Joller-Jemelka H I, Grob P J, Luthy R, Opravil M. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis . 1998; 17 6-13
27 Silva A E, McMahon B J, Parkinson A J. et al . Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. Clin Infect Dis . 1998; 26 895-897
28 Lok A S, McMahon B J. Chronic hepatitis B. Hepatology . 2001; 34 1225-1241
29 Thio C L, Seaberg E C, Skolasky R L. et al . HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet . 2002; 360 1921-1926
30 Colin J F, Cazals-Hatem D, Loriot M A. et al . Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology . 1999; 29 1306-1310
31 Gilson R JC, Hawkins A E, Beecham M R. et al . Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS . 1997; 11 597-606
32 Bodsworth N J, Cooper D A, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B carrier state. J Infect Dis . 1991; 163 1138-1140
33 Vento S, Di Perri G, Garofano T, Concia E, Bassetti D. Reactivation of hepatitis B in AIDS. Lancet . 1989; 2 108-109
34 Lazizi Y, Grangeot-Keros L, Delfraissy J F. et al . Reappearance of hepatitis B virus in immune patients infected with the human immunodeficiency virus type 1. J Infect Dis . 1988; 158 666-667
35 Biggar R J, Goedert J J, Hoofnagle J. Accelerated loss of antibody to hepatitis B surface antigen among immunodificient homosexual men infected with HIV. N Engl J Med . 1987; 316 630
36 Davies S E, Portmann B C, O'Grady J G. et al . Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology . 1991; 13 150-157
37 Fang J W, Wright T L, Lau J Y. Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B. Lancet . 1993; 342 1175
38 Scharschmidt B F, Held M J, Hollander H H. et al . Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med . 1992; 117 837-838
39 Solomon R E, Van Raden M, Kaslow R A. et al . Association of hepatitis B surface antigen and core antibody with acquisition and manifestations of human immunodeficiency virus type 1 HIV-1) infection. Am J Public Health . 1990; 80 1475-1478
40 Eskild A, Magnus P, Petersen G. et al . Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS. AIDS . 1992; 6 571-574
41 Ockenga J, Tillmann H L, Trautwein C. et al . Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol . 1997; 27 18-24
42 Saves M, Vandentorren S, Daucourt V. et al . Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe d'Epidemiologie Clinique de Sida en Aquitaine (GECSA). AIDS . 1999; 13 F115-F121
43 Sulkowski M S, Thomas D L, Chaisson R E, Moore R D. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA . 2000; 283 74-80
44 Carr A, Cooper D A. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet . 1997; 349 995-996
45 Velasco M, Moran A, Tellez M J. Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient (Letter). N Engl J Med . 1999; 340 1765-1766
46 Altfeld M, Rockstroh J K, Addo M. et al . Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J Hepatol . 1998; 29 306-309
47 Bessesen M, Ives D, Condreay L, Lawrence S, Sherman K E. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis . 1999; 28 1032-1035
48 Manegold C, Hannoun C, Wywiol A. et al . Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis . 2001; 32 144-148
49 Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR . 2002; 51 63-66
50 Collier A C, Corey L, Murphy V L, Handsfield H H. Antibody to human immunodeficiency virus and suboptimal response to hepatitis B vaccination. Ann Intern Med . 1988; 109 101-105
51 Odaka N, Eldred L, Cohn S. et al . Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccines in homosexual men. JAMA . 1988; 260 3635-3637
52 Bruguera M, Cremades M, Salinas R. et al . Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J Clin Gastroenterol . 1992; 14 27-30
53 Keet I P, van Doornum G, Safary A, Coutinho R A. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. AIDS . 1992; 6 509-510
54 Rey D, Krantz V, Partisani M. et al . Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine . 2000; 18 1161-1165
55 Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet . 2000; 355 561-565
56 Vento S, Garofano T, Renzini C. et al . Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med . 1998; 338 286-290
57 Okoshi S, Igarashi M, Suda T. et al . Remote development of hepatocellular carcinoma in patients with liver cirrhosis type B serologically cured for HBs antigenemia with long- standing normalization of ALT values. Dig Dis Sci . 2002; 47 2002-2006
58 Higashi Y, Tada S, Miyase S. et al . Correlation of clinical characteristics with detection of hepatitis B virus X gene in liver tissue in HBsAg-negative, and HCV-negative hepatocellular carcinoma patients. Liver . 2002; 22 374-379
59 Lopez V A, Bourne E J, Lutz M W, Condreay L D. Assessment of the COBAS Amplicor HBV Monitor Test for quantitation of serum hepatitis B virus DNA levels. J Clin Microbiol . 2002; 40 1972-1976
60 Brook M G, Karayiannis P, Thomas H C. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy?. <~>A statistical analysis of predictive factors. Hepatology . 1989; 10 761-763
61 Perrillo R P, Schiff E R, Davis G L. et al . A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med . 1990; 323 295-301
62 Perrillo R, Tamburro C, Regenstein F. et al . Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology . 1995; 109 908-916
63 Wong D K, Cheung A M, O'Rourke K. et al . Effect of alfa-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med . 1993; 119 312-323
64 Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. J Viral Hepat . 1998; 5 389-397
65 Fattovich G, Giustina G, Realdi G. et al . Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology . 1997; 26 1338-1342
66 Wong D K, Yim C, Naylor C D. et al . Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology . 1995; 108 165-171
67 McDonald J A, Caruso L, Karayiannis P. et al . Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon. Hepatology . 1987; 7 719-723
68 Di Martino V, Thevenot T, Boyer N, Degos F, Marcellin P. Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus-infected patients. Hepatology . 2000; 31 1030-1031
69 Di Martino V, Lunel F, Cadranel J F. et al . Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B. J Viral Hepat . 1996; 3 253-260
70 Marcellin P, Boyer N, Colin J F. et al . Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine. Gut . 1993; 34(Suppl 2) S106
71 Zylberberg H, Jiang J, Pialoux G. et al . Alpha-interferon for chronic active hepatitis B in human immunodeficiency virus-infected patients. Gastroenterol Clin Biol . 1996; 20 968-971
72 Visco G, Alba L, Grisetti S. et al . Zidovudine plus interferon alfa-2b treatment in patients with HIV and chronic active viral hepatitis. Gut . 1993; 34(Suppl 2) S107-S108
73 Fried M W, Shiffman M L, Reddy K R. et al . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med . 2002; 347 975-982
74 Cooksley W G, Piratvisuth T, Wang Y J. et al . 40 kDa peginterferon alfa-2A (PEGASYS): efficacy and safety results from a phase II, randomized actively controlled, multicenter study in the treatment of HBeAg positive chronic hepatitis B. Hepatology . 2001; 34 349A
75 Dienstag J L, Schiff E R, Wright T L. et al . Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med . 1999; 341 1256-1263
76 Lai C L, Chien R N, Leung N WY. et al . A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med . 1998; 339 61-68
77 Chien R N, Liaw Y F, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology . 1999; 30 770-774
78 Song B C, Suh D J, Lee H C, Chung Y H, Lee Y S. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology . 2000; 32 803-806
79 Pil H S, Kwang-Hyub H, Hoon A S. et al . Additional lamivudine therapy after HBeAg seroconversion would prolong the durability of response in HBV endemic area. Hepatology . 2001; 34 322A
80 Tassopoulos N C, Volpes R, Pastore G. et al . Efficacy of lamivudine in patients with hepatitis B e antigen- negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology . 1999; 29 889-896
81 Benhamou Y, Katlama C, Lunel F. et al . Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med . 1996; 125 705-712
82 Dore G J, Cooper D A, Barrett C. et al . Dual efficacy of lamivudine treatment in human immunodeficiency virus/ hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis . 1999; 180 607-613
83 Zollner B, Petersen J, Schroter M. et al . 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet . 2001; 357 934-935
84 Stuyver L J, Locarnini S A, Lok A. et al . Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology . 2001; 33 751-757
85 Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS . 2002; 16 131-133
86 Benhamou Y, Bochet M, Thibault V. et al . Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology . 1999; 30 1302-1306
87 Yuen M F, Sablon E, Hui C K. et al . Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology . 2001; 34 785-791
88 Lim S G, Wai C T, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut . 2002; 51 597-599
89 Liaw Y F, Leung N W, Chang T T. et al . Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology . 2000; 119 172-180
90 Peters M, Hann H W, Martin P. et al . Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses YMDD mutant hepatitis B virus replication: 48 week preliminary analysis. Hepatology . 2002; 36 374A
91 Marcellin P, Chang T T, Lim S G. et al . Adefovir dipivoxil for the treatment of patients with HBe antigen-positive chronic hepatitis B. New Engl J Med . 2003; 348 808-816
92 Werle B, Wursthorn K, Petersen J. et al . Quantitative analyses of hepatic HBV cccDNA during the natural history of chronic hepatitis B and adefovir dipivoxil therapy: an international, multicenter study. Hepatology . 2002; 36 296A
93 Xiung S, Yang H, Westland C. et al .Resistance surveillance of HBeAg-chronic hepatitis B patients treated for two years with adefovir dipivoxil. 11th International Symposium on Viral Hepatitis and Liver Disease, 2003, Abstract 779
94 Benhamou Y, Bochet M, Thibault V. et al . Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet . 2001; 358 718-723
95 Nunez M, Perez-Olmeda M, Diaz B. et al . Activity of tenofovir on hepatitis B virus replication in HIV-co- infected patients failing or partially responding to lamivudine. AIDS . 2002; 16 2352-2354
96 Delaugerre C, Marcelin A G, Thibault V. et al . Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother . 2002; 46 1586-1588
97 Chang T T, Hadziyannis S, Cianciara J. et al . Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects withchronic hepatitis B who have failed lamivudine. Hepatology . 2002; 36 300A
98 Gish R, Leung N W, Wang C. et al . Antiviral activity, safety, and incidence of resistance in chronically infected hepatitis B patients given once daily emtricitabine for 2 years. Hepatology . 2002; 36 372A
99 Lai C L, Leung N W, Teo E K. et al . International multicenter trial of LdT (telbividine) alone and in combination with lamivudine for chronic hepatitis B: an interim analysis. Hepatology . 2002; 36 301A
100 Barbaro G, Zechini F, Pellicelli A M. et al . Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol . 2001; 35 406-411
101 Schalm S W, Heathcote J, Cianciara J. et al . Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut . 2000; 46 562-568
102 Markowitz J S, Martin P, Conrad A J. et al . Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology . 1998; 28 585-589